National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting, 47470 [2014-19147]
Download as PDF
<![CDATA[
47470
Federal Register / Vol. 79, No. 156 / Wednesday, August 13, 2014 / Notices
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: November 12, 2014.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 9 and
10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, National Institutes of Health,
National Cancer Institute, Coordinating
Center for Clinical Trials, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 7, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–19145 Filed 8–12–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
VerDate Mar<15>2010
18:15 Aug 12, 2014
Jkt 232001
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council
Date: September 8, 2014.
Open: 8:30 a.m. to 11:30 a.m.
Agenda: Discussion of Program Policies.
Place: National Institutes of Health,
Building 31, 6th Floor, Room 6C6, 31 Center
Drive, Bethesda, MD 20892.
Closed: 12:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 6th Floor, Room 6C6, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Laura K. Moen, Ph.D.
Director, Division of Extramural Research
Activities, NIAMS/NIH, 6700 Democracy
Boulevard, Suite 800, Bethesda, MD 20892,
301–451–6515 moenl@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: August 7, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–19147 Filed 8–12–14; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0121]
Agency Information Collection
Activities: Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery; Extension,
Without Change, of a Currently
Approved Collection
ACTION:
60-Day Notice.
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration Services (USCIS) invites
the general public and other Federal
agencies to comment upon this
proposed extension of a currently
approved collection of information
‘‘Generic Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery’’ for approval under the
Paperwork Reduction Act (PRA) (44
U.S.C. 3501 et. seq.). This collection was
developed as part of a Federal
Government-wide effort to streamline
the process for seeking feedback from
the public on service delivery.
DATES: Comments are encouraged and
will be accepted for 60 days until
October 14, 2014.
ADDRESSES: All submissions received
must include the OMB Control Number
1615–0121 in the subject box, the
agency name and Docket ID USCIS–
2014–0008. To avoid duplicate
submissions, please use only one of the
following methods to submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal Web site at
www.regulations.gov under e-Docket ID
number USCIS–2014–0008;
(2) Email. Submit comments to
USCISFRComment@uscis.dhs.gov;
(3) Mail. Submit written comments to
DHS, USCIS, Office of Policy and
Strategy, Chief, Regulatory Coordination
Division, 20 Massachusetts Avenue
NW., Washington, DC 20529–2140.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Abstract
The information collection activity
will garner qualitative customer and
stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. By
qualitative feedback we mean
information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 79, Number 156 (Wednesday, August 13, 2014)]
[Notices]
[Page 47470]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-19147]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Arthritis and Musculoskeletal and Skin Diseases Advisory
Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
>Name of Committee: National Arthritis and Musculoskeletal and
Skin Diseases Advisory Council
Date: September 8, 2014.
Open: 8:30 a.m. to 11:30 a.m.
Agenda: Discussion of Program Policies.
Place: National Institutes of Health, Building 31, 6th Floor,
Room 6C6, 31 Center Drive, Bethesda, MD 20892.
Closed: 12:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 6th Floor,
Room 6C6, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Laura K. Moen, Ph.D. Director, Division of
Extramural Research Activities, NIAMS/NIH, 6700 Democracy Boulevard,
Suite 800, Bethesda, MD 20892, 301-451-6515 moenl@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
Dated: August 7, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-19147 Filed 8-12-14; 8:45 am]
BILLING CODE 4140-01-P
